Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2022-03-01

Original market date: See footnote 1

2014-01-07

Lot number: See footnote 2

0C36651JU

Expiry date: See footnote 2

2021-11-30

Product name:

JAMP-IBUPROFEN

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02401290

Product Monograph/Veterinary Labelling:

Date: 2013-01-31 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

JAMP PHARMA CORPORATION
1310 Rue Nobel
Boucherville
Quebec
Canada J4B 5H3

Class:

Human

Dosage form(s):

Tablet

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

OTC

 

American Hospital Formulary Service (AHFS): See footnote 3

28:08.04.92 

Anatomical Therapeutic Chemical (ATC): See footnote 4

M01AE01 IBUPROFEN

Active ingredient group (AIG) number:See footnote5

0108883002

List of active ingredient(s)
Active ingredient(s) Strength
IBUPROFEN 400 MG
Version 4.0.2
Date modified: